Definition, evaluation, and classification of renal osteodystrophy:​ a position statement from Kidney Disease:​ Improving Global Outcomes (KDIGO)

Moe, S.; Drüeke, T.; Cunningham, J.; Goodman, W.; Martin, K.; Olgaard, K.; Ott, S.; Sprague, S.; Lameire, N.; Eknoyan, G.

Affiliations

¹Indiana University School of Medicine and Roudebush VAMC, Indianapolis, Indiana, USA

²Inserm Unit 507 and Division of Nephrology, Hôpital Necker, Université René Descartes, Paris, France

³The Royal Free Hospital and University College London, London, UK

⁴Division of Nephrology, UCLA Medical Center, Los Angeles, California, USA

⁵Division of Nephrology, St Louis University, St Louis, Missouri, USA

⁶Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

⁷University of Washington Medical Center, Seattle, Washington, USA

⁸Evanston Northwestern Healthcare, Feinberg School of Medicine, Northwestern University, Evanston, Illinois, USA

⁹Ghent University Hospital, Ghent, Belgium

¹⁰Baylor College of Medicine, Houston, Texas, USA

Abstract

Disturbances in mineral and bone metabolism are prevalent in chronic kidney disease (CKD) and are an important cause of morbidity, decreased quality of life, and extraskeletal calcification that have been associated with increased cardiovascular mortality. These disturbances have traditionally been termed renal osteodystrophy and classified based on bone biopsy. Kidney Disease: Improving Global Outcomes (KDIGO) sponsored a Controversies Conference on Renal Osteodystrophy to (1) develop a clear, clinically relevant, and internationally acceptable definition and classification system, (2) develop a consensus for bone biopsy evaluation and classification, and (3) evaluate laboratory and imaging markers for the clinical assessment of patients with CKD. It is recommended that (1) the term renal osteodystrophy be used exclusively to define alterations in bone morphology associated with CKD, which can be further assessed by histomorphometry, and the results reported based on a unified classification system that includes parameters of turnover, mineralization, and volume, and (2) the term CKD-Mineral and Bone Disorder (CKD-MBD) be used to describe a broader clinical syndrome that develops as a systemic disorder of mineral and bone metabolism due to CKD, which is manifested by abnormalities in bone and mineral metabolism and/or extra-skeletal calcification. The international adoption of these recommendations will greatly enhance communication, facilitate clinical decision-making, and promote the evolution of evidence-based clinical practice guidelines worldwide.

Links

DOI: 10.1038/sj.ki.5000414

PubMed: 16641930

WoS: 000238112100012

History

Received: 2006-02-14

Revised: 2006-02-21

Accepted: 2006-02-21

Online: 2006-06-1

Cited Works (1)

Year	Entry
1987	Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res. December 1987;2(6):595-610.

Cited By (33)

Year	Entry
2011	Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:121-145.
2020	Aaltonen L, Koivuviita N, Seppänen M, Tong X, Kröger H, Löyttyniemi E, Metsärinne K. Correlation between ¹⁸F-Sodium Fluoride positron emission tomography and bone histomorphometry in dialysis patients. Bone. May 2020;134:115267.
2020	Novel-Catin E, Pelletier S, Fouque D, Roux J-P, Chapurlat R, D'Haese P, Behets G, Evenepoel P, Nickolas TL, Lafage-Proust M-H. Quantitative histomorphometric analysis of halved iliac crest bone biopsies yield comparable ROD diagnosis as full 7.5mm wide samples. Bone. September 2020;138:115460.
2021	Salam S, Gallagher O, Hughes D, Khwaja A, Eastell R. The role of static bone histomorphometry in diagnosing renal osteodystrophy. Bone. January 2021;142:115689.
2021	Hildebrand S, Cunningham J. Is there a role for bisphosphonates in vascular calcification in chronic kidney disease? Bone. January 2021;142:115751.
2020	Fujita R, Ota M, Sato D, Nakazawa D, Kimura-Suda H, Nakamura F, Shimizu T, Kobayashi H, Iwasaki N, Takahata M. Comparison of the efficacy and renal safety of bisphosphonate between low-dose/high-frequency and high-dose/low-frequency regimens in a late-stage chronic kidney disease rat model. Calcif Tiss Int. October 2020;107(4):389-402.
2021	Bacchetta J, Bernardor J, Garnier C, Naud C, Ranchin B. Hyperphosphatemia and chronic kidney disease: a major daily concern both in adults and in children. Calcif Tiss Int. January 2021;108(1):116-127.
2021	Cannata-Andía J, Carrillo-López N, Ferreira A. Bone in CKD, a fascinating evolving topic. Calcif Tiss Int. April 2021;108(4):407-409.
2021	Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J, Rodríguez-Carrio J, Bande-Fernández JJ, Alonso-Montes C, Carrillo-López N. Chronic kidney disease—mineral and bone disorders: pathogenesis and management. Calcif Tiss Int. April 2021;108(4):410-422.
2021	Mazzaferro S, Bagordo D, Martini ND, Pasquali M, Rotondi S, Tartaglione L, Stenvinkel P; ERA-EDTA CKD-MBD working group. Inflammation, oxidative stress, and bone in chronic kidney disease in the osteoimmunology era. Calcif Tiss Int. April 2021;108(4):452-460.
2021	Leal DV, Ferreira A, Watson EL, Wilund KR, Viana JL. Muscle-bone crosstalk in chronic kidney disease: the potential modulatory effects of exercise. Calcif Tiss Int. April 2021;108(4):461-475.
2021	Komaba H, Ketteler M, Cunningham J, Fukagawa M. Old and new drugs for the management of bone disorders in CKD. Calcif Tiss Int. April 2021;108(4):486-495.
2021	Jørgensen HS, David K, Salam S, Evenepoel P; European Renal Osteodystrophy (EUROD) workgroup, an initiative of the CKD-MBD working group of the ERA-EDTA. Traditional and non-traditional risk factors for osteoporosis in CKD. Calcif Tiss Int. April 2021;108(4):496-511.
2021	Bover J, Ureña-Torres P, Cozzolino M, Rodríguez-García M, Gómez-Alonso C. The non-invasive diagnosis of bone disorders in CKD. Calcif Tiss Int. April 2021;108(4):512-527.
2021	Ferreira AC, Cohen-Solal M, D’Haese PC, Ferreira A; European Renal Osteodystrophy (EUROD), an initiative of the CKD-MBD working group of the ERA-EDTA. The role of bone biopsy in the management of CKD-MBD. Calcif Tiss Int. April 2021;108(4):528-538.
2021	Pimentel A, Ureña-Torres P, Bover J, Fernandez-Martín JL, Cohen-Solal M. Bone fragility fractures in CKD patients. Calcif Tiss Int. April 2021;108(4):539-550.
2010	Bacchetta J, Boutroy S, Vilayphiou N, Juillard L, Guebre-Egziabher F, Rognant N, Sornay-Rendu E, Szulc P, Laville M, Delmas PD, Fouque D, Chapurlat R. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Miner Res. April 2010;25(4):849-857.
2020	Vorland CJ, Biruete A, Lachcik PJ, Srinivasan S, Chen NX, Moe SM, Hill Gallant KM. Kidney disease progression does not decrease intestinal phosphorus absorption in a rat model of chronic kidney disease–mineral bone disorder. J Bone Miner Res. February 2020;35(2):333-342.
2020	Chen NX, Srinivasan S, O'Neill K, Nickolas TL, Wallace JM, Allen MR, Metzger CE, Creecy A, Avin KG, Moe SM. Effect of advanced glycation end‐products (AGE) lowering drug ALT‐711 on biochemical, vascular, and bone parameters in a rat model of CKD‐MBD. J Bone Miner Res. March 2020;35(3):608-617.
2020	Pazianas M, Miller PD. The CKD‐MBD syndrome: hysteresis in PTH involvement and PTH administration for its management. J Bone Miner Res. December 2020;35(12):2313-2317.
2021	Fusaro M, Cozzolino M, Plebani M, Iervasi G, Ketteler M, Gallieni M, Aghi A, Locatelli F, Cunningham J, Salam S, Zaninotto M, Ravera M, Russo D, Mereu MC, Giannini S, Brandi ML, Ferrari S, Sella S, Egan CG, Bellasi A, Lullo LD, Tripepi G, Nickolas T. Sevelamer use, vitamin K levels, vascular calcifications, and vertebral fractures in hemodialysis patients: results from the VIKI study. J Bone Miner Res. March 2021;36(3):500-509.
2021	Mace ML, Gravesen E, Nordholm A, Egstrand S, Morevati M, Nielsen C, Kjaer A, Behets G, D'Haese P, Olgaard K, Lewin E. Chronic kidney disease–induced vascular calcification impairs bone metabolism. J Bone Miner Res. March 2021;36(3):510-522.
2022	Chiu H-W, Hou Y-C, Lu C-L, Lu K-C, Liu W-C, Shyu J-F, Chang J-F, Zheng C-M. Cinacalcet improves bone parameters through regulation of osteoclast endoplasmic reticulum stress, autophagy, and apoptotic pathways in chronic kidney disease–mineral and bone disorder. J Bone Miner Res. February 2022;37(2):215-225.
2022	Damrath JG, Moe SM, Wallace JM. Calcimimetics alter periosteal and perilacunar bone matrix composition and material properties in early chronic kidney disease. J Bone Miner Res. July 2022;37(7):1297-1306.
2022	Pereira L, Magalhães J, Mendonça L, Neto R, Santos J, Carvalho CG, Oliveira A, Beco A, Frazão J. Evaluation of renal osteodystrophy and serum bone-related biomarkers in a peritoneal dialysis population. J Bone Miner Res. September 2022;37(9):1689-1699.
2009	KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int. August 2009;76(suppl 113):S1-S130.
2020	Hyun YY, Lee K-B, Han SH, Choi KH, Park HC, Oh YK, Park SK, Oh K-H, Ahn C; KoreaN cohort study for Outcome in patients With CKD (KNOW-CKD) Study Group. Risk factors and renal outcomes of low bone mineral density in patients with non-dialysis chronic kidney disease. Osteoporos Int. December 2020;31(12):2373-2382.
2017	Heveran CM. Bone Tissue Material Properties Are Altered in Chronic Kidney Disease to Lower Fracture Resistance Determining Bone Quality [PhD thesis]. University of Colorado; 2017.
2015	Newman CL. Assessing and Modifying Bone Quality in Chronic Kidney Disease [PhD thesis]. Indianapolis, IN: Indiana University; May 2015.
2022	Swallow EA. Approaches to Improve the Structure and Function of the Skeleton in Chronic Kidney Disease [PhD thesis]. Indianapolis, IN: Indiana University; March 2022.
2023	Tippen SP. Interactions Between Aging and Chronic Kidney Disease on the Skeleton [PhD thesis]. Indianapolis, IN: Indiana University; May 2023.
2022	Ramil G. Using Time-Lapse HR-PQCT for Bone Turnover Classification in CKD-MBD Patients [Master's thesis]. San Francisco, University of California; 2022.
2020	Sharma AK. Evaluation of Renal Bone Disease: Advancing Our Understanding of Associations and Diagnostic Challenges [PhD thesis]. University of Melbourne; April 2020.